Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

27/07/2015 - 2 minutes

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans?

Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced three days ago that it received European market approval for its rival therapy… bittersweet news for Sanofi.

Both companies are using an antibody targeting PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or “bad” cholesterol, from the blood.

In Europe, 54% of adults express a raise in their cholesterol level. The condition is recognized as a major risk factor for cardiovascular diseases and kills around 2.6 million people each year, according to the WHO. Despite statins or other lipid-lowering therapies, many patients simply can’t keep their cholesterol level under control.

Regarding the huge size of the market,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: